Interleukin-15, human recombinant

Generic Name
Interleukin-15, human recombinant
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
HRJ300HC9W
Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Phase 2
Terminated
Conditions
Clear-Cell Renal Carcinoma
Interventions
Drug: rhIL-15
Biological: Avelumab
First Posted Date
2019-11-04
Last Posted Date
2022-05-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
2
Registration Number
NCT04150562
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

First Posted Date
2019-04-05
Last Posted Date
2022-09-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
8
Registration Number
NCT03905135
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

First Posted Date
2018-11-29
Last Posted Date
2022-03-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
1
Registration Number
NCT03759184
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

First Posted Date
2018-01-03
Last Posted Date
2024-07-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
50
Registration Number
NCT03388632
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy